Researchers identify new drug target for schizophrenia

August 13, 2012

(Medical Xpress) -- Researchers at Mount Sinai School of Medicine may have discovered why certain drugs to treat schizophrenia are ineffective in some patients. Published online in Nature Neuroscience, the research will pave the way for a new class of drugs to help treat this devastating mental illness, which impacts one percent of the world's population, 30 percent of whom do not respond to currently available treatments.

A team of researchers at Mount Sinai School of Medicine set out to discover what epigenetic factors, or external factors that influence , are involved in this treatment-resistance to atypical antipsychotic drugs, the standard of care for schizophrenia. They discovered that, over time, an enzyme in the brains of schizophrenic patients analyzed at autopsy begins to compensate for the prolonged caused by antipsychotics, resulting in reduced efficacy of the drugs.

"These results are groundbreaking because they show that may be caused by the very medications prescribed to treat schizophrenia, when administered chronically," said Javier Gonzalez-Maeso, PhD, Assistant Professor of Psychiatry and Neurology at Mount Sinai School of Medicine and lead investigator on the study.

They found that an enzyme called HDAC2 was highly expressed in the brain of mice chronically treated with antipsychotic drugs, resulting in lower expression of the receptor called mGlu2, and a recurrence of . A similar finding was observed in the postmortem brains of . The research team administered a chemical called suberoylanilide hydroxamic acid (SAHA), which inhibits the entire family of HDACs. They found that this treatment prevented the detrimental effect of the antipsychotic called clozapine on mGlu2 expression, and also improved the therapeutic effects of in mouse models.

Previous research conducted by the team showed that chronic treatment with the antipsychotic clozapine causes repression of mGlu2 expression in the frontal cortex of mice, a brain area key to cognition and perception. The researchers hypothesized that this effect of clozapine on mGlu2 may play a crucial role in restraining the therapeutic effects of antipsychotic drugs.

"We had previously found that chronic antipsychotic drug administration causes biochemical changes in the brain that may limit the therapeutic effects of these drugs,"said Dr. Gonzalez-Maeso. "We wanted to identify the molecular mechanism responsible for this biochemical change, and explore it as a new target for new drugs that enhance the therapeutic efficacy of antipsychotic drugs."

Mitsumasa Kurita, PhD, a postdoctoral fellow at Mount Sinai and the lead author of the study, said, "We found that trigger an increase of HDAC2 in frontal cortex of individuals with schizophrenia, which then reduces the presence of mGlu2, and thereby limits the efficacy of these drugs," said

Dr. Gonzalez-Maeso's team is now developing compounds that specifically inhibit HDAC2 as adjunctive treatments to antipsychotics. The study was funded by the National Institutes of Health.

Explore further: Researchers develop method for advancing development of antipsychotic drugs

Related Stories

Recommended for you

People match confidence levels to make decisions in groups

May 26, 2017

When trying to make a decision with another person, people tend to match their confidence levels, which can backfire if one person has more expertise than the other, finds a new study led by UCL and University of Oxford researchers.

Optic probes shed light on binge-eating

May 26, 2017

Activating neurons in an area of the brain not previously associated with feeding can produce binge-eating behavior in mice, a new Yale study finds.

Study finds gray matter density increases during adolescence

May 26, 2017

For years, the common narrative in human developmental neuroimaging has been that gray matter in the brain - the tissue found in regions of the brain responsible for muscle control, sensory perception such as seeing and hearing, ...

Game study not playing around with PTSD relief

May 26, 2017

Post-traumatic stress disorder (PTSD) patients wrestling with one of its main symptoms may find long-term relief beyond medication thanks to the work of a Western researcher.

Researchers identify brain network organization changes

May 25, 2017

As children age into adolescence and on into young adulthood, they show dramatic improvements in their ability to control impulses, stay organized, and make decisions. Those executive functions of the brain are key factors ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

tadchem
5 / 5 (1) Aug 13, 2012
Many schizophrenics develop an apparent resistance to the treatments, and increased dosage does little to help. My late brother found that after a while only ethanol would mute the interminable chatter of the internal voices. He traded his health and a large portion of his life expectancy for peace *within* his mind.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.